Arbutus Biopharma Corp Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Arbutus Biopharma Corp (ABUS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $4.32 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- Arbutus Biopharma Corp share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2014 was 13.63 CAD/shares, a 81.25% increase from fiscal 2013.
- Arbutus Biopharma Corp share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2013 was 7.52 CAD/shares, a 80.77% increase from fiscal 2012.
- Arbutus Biopharma Corp share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2012 was 4.16 CAD/shares.
CAD/shares
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2014-12-31 | 13.63 CAD/shares 10-K · filed 2015-03-13 |
| 2013-12-31 | 7.52 CAD/shares 10-K · filed 2015-03-13 |
| 2012-12-31 | 4.16 CAD/shares 10-K · filed 2015-03-13 |
USD/shares
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.32 10-Q · filed 2026-08-12 | $4.37 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | $4.39 10-Q · filed 2026-05-13 | |||
| 2025-09-30 | $3.39 10-Q · filed 2025-11-13 | $3.33 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $3.34 10-Q · filed 2026-08-12 | $3.32 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $3.31 10-Q · filed 2026-05-13 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-13 | $2.49 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $3.27 10-Q · filed 2025-08-06 | $2.49 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $2.40 10-Q · filed 2025-05-14 | |||
| 2023-09-30 | $2.25 10-Q · filed 2024-11-06 | $2.78 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $2.75 10-Q · filed 2024-08-08 | $2.88 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $2.90 10-Q · filed 2024-05-02 | |||
| 2022-09-30 | $2.37 10-Q · filed 2023-11-07 | $2.77 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $2.33 10-Q · filed 2023-08-03 | $2.78 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $2.81 10-Q · filed 2023-05-04 | |||
| 2021-09-30 | $3.70 10-Q · filed 2022-11-09 | $4.19 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $3.03 10-Q · filed 2022-08-04 | $4.23 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $4.33 10-Q · filed 2022-05-05 | |||
| 2020-09-30 | $2.25 10-Q · filed 2021-11-04 | $3.21 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $3.00 10-Q · filed 2021-08-05 | $3.27 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $3.35 10-Q · filed 2021-05-05 | |||
| 2019-09-30 | $1.57 10-Q · filed 2020-11-05 | $3.41 10-Q · filed 2020-11-05 | ||
| 2014-12-31 | $12.34 10-K · filed 2015-03-13 | |||
| 2013-12-31 | $7.30 10-K · filed 2015-03-13 | |||
| 2012-12-31 | $4.16 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |